OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Picozzi on Prognostic Value of Pathologic Response to Chemo in Pancreatic Cancer

April 24th 2020

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

April 24th 2020

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Dr. Pothuri on the Importance of Obtaining Patient-Reported Outcomes in Ovarian Cancer

April 24th 2020

Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.

Dr. Grossbard on the Activity of Venetoclax in Follicular Lymphoma

April 24th 2020

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Dr. Raje on the Potential Utility of Belantamab Mafodotin in Multiple Myeloma

April 24th 2020

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.

Dr. Altomare on the Challenges of Treating ITP

April 24th 2020

Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.

Dr. Fader on Trastuzumab/Chemo in HER2+ Uterine Serous Carcinoma

April 24th 2020

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Dr. Hamid on Next Steps for Precision Medicine in mHSPC

April 24th 2020

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.

Dr. Hwang on the Utility of Docetaxel in mCSPC

April 24th 2020

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Lopes on Providing Optimal Cancer Care Despite COVID-19

April 24th 2020

Gilberto De Lima Lopes, MD, discusses how he navigates challenges caused by COVID-19 to continue to provide optimal care to his patients with cancer.

Dr. Cortes on the Challenges of Using Ruxolitinib in MPNs

April 24th 2020

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Dr. Huey on Navigating the Landscape of HCC

April 24th 2020

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).

Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian Cancer

April 23rd 2020

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

Dr. Chung on Adding Dietary Supplements to Chemotherapy in Pancreatic Cancer

April 23rd 2020

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Dr. Feldman on the Utility of PET Scan in Hodgkin Lymphoma

April 23rd 2020

Tatyana Feldman, MD, discusses the utility of PET Scan in Hodgkin Lymphoma.

Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in Myelofibrosis

April 23rd 2020

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

Dr. Chang on Questions Regarding Molecular Testing in Prostate Cancer

April 23rd 2020

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

Dr. Grivas on the Future of Molecular Subtyping in Urothelial Cancer

April 23rd 2020

Petros Grivas, MD, PhD, discusses the future of molecular subtyping in urothelial cancer.

Dr. Oh on the Importance of Identifying DNA Damage Repair Mutations in Prostate Cancer

April 23rd 2020

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Dr. Shah on the Role of Venetoclax in Multiple Myeloma

April 23rd 2020

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of venetoclax (Venclexta) in multiple myeloma.